ArticleRheumatology (Oxford, England)2025
Development and internal validation of a clinical and genetic risk score for rheumatoid arthritis-associated interstitial lung disease.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 16 citations in OpenAlex.
- The evolving comorbidity landscape of rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Validation of a Genetic Risk Score Combined With Clinical Variables for Predicting Pulmonary Fibrosis in Early Rheumatoid Arthritis.Arthritis care & research · 2026Article
- Heterogeneity in the association of genetic risk for RA and resultant RA phenotypes.Rheumatology (Oxford, England) · 2026Article
- Computational approaches to multimodal data integration in rheumatoid arthritis: from data landscape to clinical translation.Briefings in bioinformatics · 2026Review
- Development and External Validation of a Genetic Risk Score for Pain in Rheumatoid Arthritis.Arthritis care & research · 2025Article
- Comparable area under the curve for three risk scores to detect interstitial lung disease in patients with rheumatoid arthritis: an external validation.Rheumatology international · 2025Article
- Lung involvement in rheumatoid arthritis, a prospective study.ERJ open research · 2025Article
- A multi-biomarker machine learning approach for early prediction of interstitial lung disease in rheumatoid arthritis.BMC pulmonary medicine · 2025Article
- Peripheral Biomarker Signatures in Rheumatoid Arthritis-Associated Interstitial Lung Disease.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- Polygenic risk scores for rheumatoid arthritis and idiopathic pulmonary fibrosis and associations with RA, interstitial lung abnormalities, and quantitative interstitial abnormalities among smokers.Seminars in arthritis and rheumatism · 2025Article
- Genetically-determined variation in CRP impacts disease activity assessment in rheumatoid arthritis.Rheumatology (Oxford, England) · 2025Observational
- The Veterans Affairs Rheumatoid Arthritis Registry: A unique population in rheumatoid arthritis research.Seminars in arthritis and rheumatism · 2025Review
- Rheumatoid arthritis-associated interstitial lung disease: Advancing the identification and management.Seminars in arthritis and rheumatism · 2025Review
- Genetic Risk Scores for the Clinical Rheumatologist.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2025Review
- Moving forward in Rheumatoid Arthritis-Associated Interstitial Lung Disease Screening.Journal of clinical medicine · 2024Review
- Design of ANCHOR-RA: a multi-national cross-sectional study on screening for interstitial lung disease in patients with rheumatoid arthritis.BMC rheumatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 1 country.
Funding
Abstract
objectiveAlthough clinical and genetic risk factors have been identified for rheumatoid arthritis-associated interstitial lung disease (RA-ILD), there are no current tools allowing for risk stratification. We sought to develop and validate an ILD risk model in a large, multicentre, prospective RA cohort.
methodsParticipants in the Veterans Affairs RA (VARA) registry were genotyped for 12 single nucleotide polymorphisms (SNPs) associated with idiopathic pulmonary fibrosis. ILD was validated through systematic record review. A genetic risk score (GRS) was computed from minor alleles weighted by effect size with ILD, using backward selection. The GRS was combined with clinical risk factors within a logistic regression model. Internal validation was completed using bootstrapping, and model performance was assessed by the area under the receiver operating curve (AUC).
resultsOf 2386 participants (89% male, mean age 69.5 years), 9.4% had ILD. Following backward selection, five SNPs contributed to the GRS. The GRS and clinical factors outperformed clinical factors alone in discriminating ILD (AUC 0.675 vs 0.635, P < 0.001). The shrinkage-corrected performance for combined and clinical-only models was 0.667 (95% CI 0.628, 0.712) and 0.623 (95% CI 0.584, 0.651), respectively. Twenty percent of the cohort had a combined risk score below a cut-point with >90% sensitivity.
conclusionA clinical and genetic risk model discriminated ILD in a large, multicentre RA cohort better than a clinical-only model, excluding 20% of the cohort from low-yield testing. These results demonstrate the potential utility of a GRS in RA-ILD and support further investigation into individualized risk stratification and screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.